4.7 Article

Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study

Journal

DIABETES CARE
Volume 43, Issue 9, Pages 2066-2073

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/dc19-2547

Keywords

-

Funding

  1. National Institute of Diabetes and Digestive and Kidney Diseases [U01-DK-63829, U01-DK-63861, U01-DK-63821, U01-DK-63865]
  2. National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases [HHSN267200700014C]
  3. Eunice Kennedy Shriver National Institute of Child Health and Human Development
  4. National Institute of Environmental Health Sciences
  5. JDRF
  6. Centers for Disease Control and Prevention
  7. National Institutes of Health National Center for Advancing Translational Sciences Clinical and Translational Science Awards [UL1-TR-000064, UL1-TR-001082]
  8. [U01-DK-63863]
  9. [U01-DK-63836]
  10. [U01-DK-63790]
  11. [U01-DK-100238]
  12. [U01-DK-106955]
  13. [U01-DK-112243]
  14. [U01-DK-117483]
  15. [U01-DK-95300]
  16. [UC4-DK-63829]
  17. [UC4-DK-63861]
  18. [UC4-DK-63821]
  19. [UC4-DK-63865]
  20. [UC4-DK-63863]
  21. [UC4-DK-63836]
  22. [UC4-DK-95300]
  23. [UC4-DK-100238]
  24. [UC4-DK-106955]
  25. [UC4-DK-112243]
  26. [UC4-DK-117483]

Ask authors/readers for more resources

OBJECTIVE The first-appearing beta-cell autoantibody has been shown to influence risk of type 1 diabetes (T1D). Here, we assessed the risk of autoantibody spreading to the second-appearing autoantibody and further progression to clinical disease in The Environmental Determinants of Diabetes in the Young (TEDDY) study. RESEARCH DESIGN AND METHODS Eligible children with increased HLA-DR-DQ genetic risk for T1D were followed quarterly from age 3 months up to 15 years for development of a single first-appearing autoantibody (GAD antibody [GADA], insulin autoantibody [IAA], or insulinoma antigen-2 autoantibody [IA-2A]) and subsequent development of a single second-appearing autoantibody and progression to T1D. Autoantibody positivity was defined as positivity for a specific autoantibody at two consecutive visits confirmed in two laboratories. Zinc transporter 8 autoantibody (ZnT8A) was measured in children who developed another autoantibody. RESULTS There were 608 children who developed a single first-appearing autoantibody (IAA,n= 282, or GADA,n= 326) with a median follow-up of 12.5 years from birth. The risk of a second-appearing autoantibody was independent of GADA versus IAA as a first-appearing autoantibody (adjusted hazard ratio [HR] 1.12; 95% CI 0.88-1.42;P= 0.36). Second-appearing GADA, IAA, IA-2A, or ZnT8A conferred an increased risk of T1D compared with children who remained positive for a single autoantibody, e.g., IAA or GADA second (adjusted HR 6.44; 95% CI 3.78-10.98), IA-2A second (adjusted HR 16.33; 95% CI 9.10-29.29;P< 0.0001), or ZnT8A second (adjusted HR 5.35; 95% CI 2.61-10.95;P< 0.0001). In children who developed a distinct second autoantibody, IA-2A (adjusted HR 3.08; 95% CI 2.04-4.65;P< 0.0001) conferred a greater risk of progression to T1D as compared with GADA or IAA. Additionally, both a younger initial age at seroconversion and shorter time to the development of the second-appearing autoantibody increased the risk for T1D. CONCLUSIONS The hierarchical order of distinct autoantibody spreading was independent of the first-appearing autoantibody type and was age-dependent and augmented the risk of progression to T1D.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available